Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Theresa, Berent"'
Publikováno v:
Der Kardiologe. 15:509-518
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64b32cb3624fa3486d6a0a81fa3da325
https://doi.org/10.1007/s12181-021-00503-7
https://doi.org/10.1007/s12181-021-00503-7
Publikováno v:
Atherosclerosis Supplements. 40:125-130
Background Lipoprotein (Lp-) apheresis is a life-long therapy, usually performed in weekly intervals. In some cases, however, atherosclerotic disease progresses despite adequate therapy with weekly Lp-apheresis and maximal lipid lowering medication.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd24ee60c156e7706ea9ff9f5062b715
https://doi.org/10.1016/j.atherosclerosissup.2019.08.024
https://doi.org/10.1016/j.atherosclerosissup.2019.08.024
Publikováno v:
Atherosclerosis Supplements. 40:73-78
Background and aims Muscle-related symptoms with or without creatine kinase (CK) elevation are common adverse effects associated with statin use. Symptoms are ranging from benign myalgia to myositis and in rare cases to rhabdomyolysis. The aim was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f717ec7228fc02ae85ad7beeef3b7e7
https://doi.org/10.1016/j.atherosclerosissup.2019.08.026
https://doi.org/10.1016/j.atherosclerosissup.2019.08.026
Publikováno v:
Atherosclerosis Supplements. 40:8-11
Background In Austria, about 12 patients per 1 million inhabitants are treated currently with lipoprotein (LP-) apheresis. In 2016 it has been suggested, that about 5000 patients were treated worldwide with LP-apheresis, more than half of them in Ger
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d032e5ad4a64bf50f4de2596b416cb67
https://doi.org/10.1016/j.atherosclerosissup.2019.08.025
https://doi.org/10.1016/j.atherosclerosissup.2019.08.025
Publikováno v:
Der Kardiologe. 15:654-654
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97ff270663ebfe240807cfeb44509370
https://doi.org/10.1007/s12181-021-00516-2
https://doi.org/10.1007/s12181-021-00516-2
Publikováno v:
Wiener Medizinische Wochenschrift. 168:7-15
Fettstoffwechselstorungen sind sehr haufig und spielen in der Entstehung und Progression atherosklerotischer Prozesse eine wichtige Rolle. Sie konnen wirksam behandelt werden, neben der Umstellung des Lebensstils spielen medikamentose Interventionen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9eef407e2a6c0b3a47d3691534216612
https://doi.org/10.1007/s10354-017-0594-y
https://doi.org/10.1007/s10354-017-0594-y
Publikováno v:
Vasa. 47:341-343
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::add173632bbcbd1dcc5dd72c8d89c359
https://doi.org/10.1024/0301-1526/a000728
https://doi.org/10.1024/0301-1526/a000728
Publikováno v:
Wiener klinische Wochenschrift. 132(23-24)
The use of implantable cardioverter defibrillators (ICD) has been shown to improve survival in patients at risk of sudden cardiac death; however, due to the continuous risk of sudden loss of consciousness during arrhythmia or ICD intervention, they p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bb26834ca4e2a92eb4dd447dbfc29bd
https://pubmed.ncbi.nlm.nih.gov/32435868
https://pubmed.ncbi.nlm.nih.gov/32435868
Publikováno v:
VASA. Zeitschrift fur Gefasskrankheiten. 47(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::131bf647b8904d09790e546eda221069
https://pubmed.ncbi.nlm.nih.gov/29897296
https://pubmed.ncbi.nlm.nih.gov/29897296
Publikováno v:
Wiener medizinische Wochenschrift (1946). 168(1-2)
Treatment of lipid disorders (dyslipidemia) is the cornerstone of atherosclerosis prevention and reduction of progression. Lifestyle modification is the first step to improve the plasma lipid profile. Statins play a central role in the reduction of L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::25fc4111d79f8a0344ffc5e25e58f7d8
https://pubmed.ncbi.nlm.nih.gov/28913682
https://pubmed.ncbi.nlm.nih.gov/28913682